natgillin/translations-raw huggingface dataset:
The ink cartridge of claim 1, wherein the interfaces on the front face of the ink cartridge comprise an ejector alignment interface, the ejector alignment interface comprising a ring-shaped ridge. 
Uložak za tintu (3) u skladu s patentnim zahtjevom 1, naznačen time što sučelja na prednjoj površini imaju sučelje za poravnavanje izbacivača (36), gdje sučelje za poravnavanje izbacivača (36) ima prstenasti rub.
A liquid pharmaceutical composition according to claim 4, wherein the follicle-stimulating hormone (FSH) is present at a concentration of at or about 300 IU/ml to at or about 900 IU/ml. 
Tekući farmaceutski pripravak prema zahtjevu 4 naznačen time da je hormon za stimulaciju folikula (FSH) prisutan u koncentraciji od ili oko 300 TU/ml do točno ili oko 900 IU/ml.
is hydrogen, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl is each optionally substituted by one or more hydroxy, oxo, halogen, amino, lower alkyl-amino, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), lower alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aryl, aryloxy, arylalkoxy or heterocyclyl; 
Ra je vodik, aril, C;-C;> cikloalkil ili heterociklil, pri čemu aril, C3-Cy> cikloalkil ili heterociklil je svaki proizvoljno supstituiran sa jednim ili više hidroksi, okso, halogenom, amino, nižim alkil-amino, alkilom (proizvoljno supstituiranim u jednom ili više položaja sa halogenom, hidroksi ili nižim alkoksi), nižim alkoksi (proizvoljno supstituiranim u jednom ili više položaja sa halogenom ili hidroksi), karboksi, karbonilalkoksi, karbamoil, karbamoilalkilom, arilom, ariloksi, arilalkoksi ili heterociklilom;
the material (114) infused with the fragrance is a solid in the shape of a flat ring; and the cap (116) includes a vent (110) effective to disperse the fragrance. 
HR P20171283 T1 se kod materijala (114) koji je natopljen aromom, radi o krutoj tvari u obliku plosnatog prstena; i kapica (116) obuhvaća ventil (110) koji je djelotvoran za raspršivanje arome.
Accordingly, the two most important physical features of HA are the viscosity and the molecular size thereof. 
Posljedično, dva najvažnija fizikalne parametra HA su viskoznost i njegova molekularna težina.
The TGFB antagonist for use according to Claim 1, wherein said TGFB antagonist is a molecule that is capable of diminishing the activity of a TGFB. 
Komplet prema zahtjevu 9, naznačen time da navedeni TGFß antagonist je sredstvo koje blokira vezanje TGFß proteina na njegov receptor.
Each session consists of two trials. 
Svaka sesija se sastoji od dva pokusa.
combining bulk aripiprazole and a vehicle to form a primary suspension; 
(a) miješanje rasutog aripiprazola i nosača da nastane primarna suspenzija;
The compound or a pharmaceutically acceptable salt thereof of claim 8, wherein the angiogenesis-related disorder is cancer or age-related macula degeneration. 
Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 8, naznačen time da poremećaj povezan sa angiogenezom rak ili makularna degeneracija povezana sa dobi.
An indolizine derivative as claimed in claim 8, wherein R2b represents a hydrogen atom, methyl, ethyl, methoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
c predstavlja atom vodika, atom fluora, atom klora, metil, monofluorometil, difluorometil ili trifluorometil, ili prolijek, ili farmaceutski prihvatljiva sol.
A method for treating or managing a disease or a disorder mediated by AAK1 activity, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof wherein a disease or disorder mediated by AAKI activity is pain. 
Spoj bilo kojeg od patentnih zahtjeva 1 do 9, ili farmaceutski prihvatljiva sol tog spoja za primjenu u liječenju ili upravljanju bolešću ili poremećajem koji je posredovan pomoću AAK1 aktivnosti.
Manoeuvrable dredging vessel according to a preceding claim, wherein the control means operationally coupled with the controllable pitch propeller are at least partly accommodated in the hollow shaft. 
Upravljivo ploveće jaružalo u skladu s prethodnim patentnim zahtjevom, naznačeno time što je upravljački element, radno spregnut s propelerom upravljivog nagiba u najmanju ruku djelomično smješten u šupljem vratilu.
The method of claim 1, wherein the DNA obtained from a bodily fluid of a pregnant individual is cell-free DNA obtained from the plasma of the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što DNK dobivena iz tjelesne tekućine trudne osobe predstavlja DNK oslobođenu od stanica koja je dobivena iz plazme trudne osobe.
The pharmaceutical formulation according to claim 1, wherein, upon dispersion in the aqueous vehicle, the concentration of melatonin is comprised between 1.0 and 20 mg/ml. 
Farmaceutska formulacija prema patentnom zahtjevu 1, naznačeno time da je koncentracija melatonina nakon disperzije u vodeni vezikul između 1.0 120 mg/ml.
This will avoid product segregation. 
Time se izbjegava segregacija proizvoda.
A compound represented by wherein and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; 
"Spoj naznačen time, da je predstavljen Formulom 1 dh gdje R' i R* mogu biti isti ili različiti te predstavljati atom vodika ili C,-C4 alkilnu skupinu;
The composition of claim 1, wherein the viral culture comprises flavivirus and the host cell culture comprises Vero (African green monkey Vero cells), LLC-MK2 cells (monkey kidney cells) or C6/36 mosquito cells. 
Spoj sukladno patentnom zahtjevu 1, gdje kultura virusa sadrži flavi virus i stanicu kulture domaćina sadrži vero (vero stanice afričkog zelenog majmuna), LLC-MK2 stanice (stanice bubrega majmuna) ili C6/36 stanice komarca.
the single nucleotide polymorphism marker having an A at the position corresponding to position 312 in SEQ ID NO:3, 
tera /itorčbom jednostrukog nukleotida koji ima A na položaju koji odgovara položaju 312 u SEQ ID NO:3,
the mouse comprises a functional immunoglobulin light chain locus, preferably wherein the immunoglobulin light chain locus is a k light chain gene locus or a λ light chain gene locus; or the mouse is a strain selected from the group consisting of a 129 strain, a C57BL/6 strain, and a mixed 129 x C57BL/6 strain, preferably wherein the mouse is 50% 129 and 50% C57BL/6. 
(b) miš sadrži funkcionalni lokus imunoglobulinskog lakog lanca, poželjno naznačen time, što je lokus imunoglobulinskog lakog lanca lokus gena lakog lanca x ili lokus gena lakog lanca 2; i/ili (c) miš je soj odabran iz grupe koja se sastoji od soja 129, soja C57BL/6 i mješovitog soja 129 x C57BL/6, poželjno naznačen time, što je miš 50 % soj 129 1 50 % soj C57BL/6.
The method of claim 5 whereby the trioxolane is administered before or after exposure to malaria. 
Dispiro-1,2,4-trioksolan prema patentnom zahtjevu 6, pri čemu se trioksolan primjenjuje prije ili nakon izlaganja uzročniku malarije.
A demountable pole dancing stage as claimed in Claim 2 and Claim 3 or 4, wherein each rotatable support member is mounted on the hub via a pair of collars and support arms, with the inner upright member of the support member pivotally mounted on the support arms of the collars via a vertically extending rod. 
Sklopiva pozornica za ples na šipki iz zahtjeva 2 i iz zahtjeva 3 ili 4, pri čemu je svaki rotirajući nosivi element montiran na središte pomoću para spojki i nosivog kraka, s tim da je unutarnja uspravna komponenta osovinski montirana na nosive krakove putem ravno izdignute šipke.
The compounds of the formula (I) where R3 = H can also be obtained from the corresponding azido compounds, the azido group being convertable to -NH2 by reduction, e.g. with triphenylphosphine, or zinc and hydrochloric acid, or H2/Pd, under conventional conditions. 
Spojevi formule (I) gdje je R* = H mogu se dobiti iz odgovarajućih azido spojeva, pri čemu se azido grupa može prevesti u -NH> redukcijom, npr., s trifenilfosfinom, ili s cinkom i klorovodičnom kiselinom, ili s H2/Pd, pod konvencionalnim uvjetima.
with the proviso that when R1, R3, R4, and R5 are hydrogen, then R2 is not bromo; and with the further proviso that when R, R' and R" are hydrogen and q is zero, and Ra is either -COOH (p is zero) or -WR8 (p is one) and W is oxygen and R8 is hydrogen then at least one of the following occurs: 
pod uvjetom da kada R1, R3, R4, i R5 su vodik, tada R2 nije bromo; i uz dodatni uvjet da kada R, R' i R" su vodik i q je nula, i Ra je bilo -COOH (p je nula) ili -WR8 (p je jedan) i W je kisik i R8 je vodik tada se događa najmanje jedno od slijedećeg:
One or two days before each experiment, the cells were detached from the tissue culture flasks with Accutase (TCS Biologicals) using standard tissue culture methods. 
Dan do dva prije svakog eksperimenta, stanice su od posuda za uzgoj odvojene pomoću Accut-aze (TCS Biologicals), koristeći standardne tehnike stanične kulture.
or a hydrate thereof. A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of phosphoric acid, sulphuric acid, acetic acid, citric acid, maleic acid, fumaric acid, succinic acid, oxalic acid, toluenesulphonic acid and methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselnska adicijska sol (£)-3-[1-(4-dimetilaminometilbenzensulfonil)-1#-pirol-3-11]-V-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine fosforna kiselina, sumporna kiselina, octena kiselina, limunska kiselina, maleinska kiselina, fumarna kiselina, jantarna kiselina, oksalna kiselina, toluensulfonska kiselina i metansulfonska kiselina, ili njegov hidrat.
As the second guiding passage can be rotated separately, the surgeon only needs to move the tubular member with the second instrument and not the flushing unit and first endoscopic instrument, when moving the second instrument e.g. from one tissue area to another. 
Budući da drugi prolaz za vođenje može rotirati odvojeno, kirurg treba samo pomicati cijevni element s drugim instrumentom, a ne jedinicu za ispiranje i prvi endoskopski instrument, kada pomiče drugi instrument, na primjer, iz jednog predjela tkiva u neki drugi predio.
The composition as claimed in claim 5, wherein a weight fraction of phosphatidylcholine, based on all lipids, is greater than 50.0% by weight. 
Kompozicija za primjenu u postupku sukladno zahtjevu 7, naznačena time, što je težinski udio fosfatidilkolinkolina, bazirano na svim lipidima, veći od 50,0 tež. %.
The adenovirus vector of claim 43, wherein the adenovirus vector is an Ad26 vector. The adenovirus vector of claim 43, wherein the sequence that encodes SEQ ID NO: 18 comprises the nucleic acid sequence of SEQ ID NO: 26. 
prvi pripravak koji sadrži imunogeno učinkovitu količinu vektora adenovirusa, poželjno vektor adenovirusa 26, koji kodira sintetski protein ovojnice HIV-a koji ima aminokiselinsku sekvencu SEQ ID NO: 8, poželjno SEQ ID NO: 18;
A combination according to 1 or 2 wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt. 
Kombinacija u skladu s patentnim zahtjevom 1, naznačena time što je farmaceutski prihvatljiva sol spoja formule (I) natrijeva sol.
a pseudotyped AAV vector comprising a double-stranded self-complementary AAV genome derived from an AAV serotype different from the AAV9 serotype and a capsid derived from an AAV9 capsid. 
- - pseudotipizirani AAV vektor koji sadrži dvolančani samokomplementarni AAV genom deriviran iz AAV serotipa različitog od AAV9 serotipa 1 kapsidu deriviranu iz AAV9 kapside.
wherein represents a hydrogen or fluorine atom or a trifluoromethyl group; 
(D naznačen time da R' predstavlja vodikov ili fluorov atom ili skupinu trifluorometil;
Provided, that the transverse channels have a respective width, this could result in that only the transverse channels and the openings of the groove structures 4 have to be filled with a filling medium. 
Pod uvjetom da poprečni kanali imaju odgovarajuću širinu, to može imati za posljedicu da se samo poprečni kanali i otvori brazdastih struktura 4 napune s punilom.
selecting said genetically modified avian cell lines expressing said recombinant proteins or peptides; and 
odabir tih genetički modificiranih ptičjih staničnih linija koje eksprimiraju rekombinantne proteine ili peptide; i
In a more preferred embodiment, the invention provides a process for preparing 1-(3′,4′-dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid having formula (Ia): 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da spoj formule (1) jest 1-(3',4'-diklor-2fluor[1,1"-bifenil]-4-il)-ciklopropankarboksilna kiselina.
The communication method according to one of claims 6 to 8, wherein the second search space is configured on a resource which does not overlap with the first search space within the one PRB set. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 do 10, naznačen time što se drugi prostor za pretraživanje konfigurira na resursu koji se ne preklapa s prvim prostorom za pretraživanjem unutar jednog PRB skupa.
Process according to one of claims 12 to 15, wherein said curing/drying step c) is carried out by a process selected from the group consisting of physical evaporation, UV-curing, oxidative reticulation, chemical crosslinking, electron beam curing, or any combination thereof. 
Postupak prema jednom zahtjevu od 11 do 12, naznačen time da se navedeni korak stvrdnjavanja/sušenja c) provodi postupkom odabranim iz skupine koja sadrži fizikalno isparavanje, UV-stvrdnjavanje, oksidacijsku retikulaciju, kemijsko umrežavanje, stvrdnjavanje elektronskim snopom, ili bilo koju njihovu kombinaciju.
The compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in any of claims 1 to 10 including 2,3-bis(4-methoxyphenyl)-N-(6-methylpyridin-2-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide and 2,3-bis(4-methoxyphenyl)-N-pyridin-2-yl-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide for use in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease or psoriasis. 
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 10, uključujući 2,3-bis(4-metoksifenil)-N-(6-metilpiridin-2-il)-1-okso-1,2,3,4-tetrahidroizokinolin-4-karboksamid i 2,3-bis(4-metoksifenil)-N-piridin-2-il-1-okso-1,2,3,4-tetrahidroizokinolin-4-karboksamid, mazmačen time što je namijenjen upotrebi u liječenju ili inhibiranje raka, autoimune bolesti, reumatoidnog artritisa, upalne crijevne bolesti ili psorijaze.
Selective a1 adrenergic receptor agonist may be selected from oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, and amidephrine. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je selektivni agonist alfa 1 adrenergijskog receptora odabran od oksimetazolina, nafazolina, tetrahidrozolina, fenilefrina, fenilefrin hidroklorida, ksilometazolina, metoksamina, metaraminola, midodrina, desglimidodrina, cirazolina, amidefrina i njihovih kombinacija.
c = 33.075 (4) Å Y = 90°. The pharmaceutical composition according to claim 1, wherein Form I is characterized by one or more peaks at 15.4 degrees, 16.3 degrees, and 14.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation at 40 kV, 35 mA. 
Farmaceutski sastav prema zahtjevu 1, gdje je oblik I karakteriziran sa jednim ili više vrhova na 15.4 stupnjeva ± 0.2 stupnja, 16.3 stupnjeva ± 0.2 stupnja, i 14.5 stupnjeva ± 0.2 stupnja u difrakciji redgneskih zraka na prahu dobivenih pomoću Cu K alfa zračenja na 40 kV, 35 mA.
In one aspect, an isolated DNA construct is provided, comprising a contiguous region of the human λ light chain locus from hVλ5-52 downstream to the end of hVλ1-40. 
Cc) graničnu sekvenciju humanog lokusa lakog A lanca koja se proteže od hVA5-52 do hV2A1-40 1 graničnu sekvenciju humanog lokusa lakog X lanca koja se proteže od hVA3-29 do hV23-1.
It has surprisingly been found that the compounds of the invention have in vivo and in vitro activities higher than the structurally related analogues of WO03103671. 
Iznenađujuće je nađeno da spojevi iz izuma imaju in vivo i in vitro aktivnosti veće od strukturno odgovarajućih analoga iz WO 03103671.
The method of any one of claims 1-3, wherein R is methyl, R' is ethyl and R" is benzyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R metil, R′ je etil, a R″ je benzil.
La represents -0- or a single bond, and -(Succinimid-3-yl-N)- has a structure represented by the following formula: which is connected to the anti-HER2 antibody at position 3 thereof and is connected to the methylene group in the linker structure containing this structure on the nitrogen atom at position 1. 
koja je povezana sa anti-HER2 antitijelom na svojoj poziciji 3 i povezana je sa metilenskom grupom u strukturi veznika pri čemu sadrži ovu strukturu na atomu dušika na poziciji 1.
Jaw member guiding means can be provided such that the jaw members are displacable along aligned trajectories when transferring the extraction module between its closed and opened state. 
Sredstvo za vođenje elementa čeljusti može biti tako predviđeno, tako da se elementi čeljusti mogu pomicati duž poravnane putanje kada se premješta modul za ekstrakciju između zatvorenog i otvorenog položaja.
The coal feeder system of claim 1, wherein the feeder device controls the rate of coal feed to the gasifier by maintaining a feeder pressure with gas injection at different locations and by measured flow of control gas through the coal feeder system. 
Sustav opskrbe ugljenom (100) prema zahtjevu 1, naznačen time, da je opskrbni uređaj raspoređen za upravljanje brzinom izdavanja ugljena u rasplinjač (150) putem održavanja tlaka opskrbljivača s injektiranjem plina na različitim položajima 1 pomoću mjerenja protoka upravljanog plina kroz sustav opskrbe ugljenom 7.
The method of claim 1, wherein the antibody or antigen binding fragment thereof increases a serum biomarker of bone deposition selected from the group consisting of total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, and type-I procollagen (C-terminal/N-terminal). 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što protutijelo ili njegov ulomak koji veže antigen povećava biomarker seruma odlaganja kosti odabran iz skupine koju čine ukupna alkalna fosfataza, alkalna fosfataza specifična za kosti, osteokalcin, i prokolagen tip-I (C-terminalni/N-terminalni).
An N-terminal removal step has been developed which reduces the N-terminal variants to a range of 0-2%. 
(d) održavanje uvjeta aktivacije dok su N-terminalne varijante reducirane na raspon od 0-2%.
at least one component b2), at least one component b3), at least one component b4) and at least one component b5); 
- barem jednu komponentu b2), barem jednu komponentu b3), barem jednu komponentu b4) i barem jednu komponentu b5);
is thienyl or phenyl, said thienyl or phenyl substituted with 2 or 3 of the same or different halo atoms; and 
R. je tienil ili fenil, gdje je navedeni tienil ili fenil supstituiran s 2 ili 3 ista ili različita atoma halogena;
Compound, enantiomer or mixtures thereof or solvate thereof according to claim 7 for use in the treatment and/or prevention of a central nervous system disorder. 
Spoj, enantiomer ili njegove smjese ili njegov solvat u skladu s patentnim zahtjevom 7, naznačen time što je namijenjen upotrebi u liječenju i/ili sprječavanje poremećaja središnjeg živčanog sustava.
Detailed Description of Preferred Examples of the Invention 
Datum objave europske prijave patenta:
wherein the first polypeptide, the second polypeptide or both the first and second polypeptides comprise an intracellular costimulatory polypeptide, and 
Heterodimerni, uvjetno aktivni CAR u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da prvi polipeptid, drugi polipeptid ili oba sadrže ko-stimulacijski polipeptid.
A method according to claim 27 wherein the primer set for amplification of the Endochitinase 42 gene (ech42) has sequence SEQIDNO: 1 and SEQIDNO: 2 and wherein the primer set for amplification of the G protein a subunit gene (tga3) has sequence SEQIDNO: 4 and SEQIDNO: 5. 
Postupak prema patentnom zahtjevu 27 gdje set prajmera za amplifikaciju gena Endohitinaze 42 (ech42) ima sekvencu SEQ ID NO: 1 i SEQ ID NO: 2 i gdje set prajmera za amplifikaciju gena a podjedinice G proteina (tga3) ima sekvencu SEQ ID NO: 4 i SEQ ID NO: 5.
The compound according to claim 1 that is selected from the following table, or a pharmaceutically acceptable salt or prodrug thereof: 
11. Spoj prema zahtjevu 1, naznačen time da je izabran 1z slijedeće tablice:
A compound selected from: and or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof. 
Spoj formule (I), [image] ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili hidrat, naznačen time što:
The formulation according to claim 3 containing the antibody in an amount of at least 50 mg/ml. 
Formulacija prema zahtjevu 3 naznačena time da sadrži protutijelo u količini od barem 50 mg/ml.
(IIg): wherein the stereoisomeric configuration of carbon-1 and carbon-3 of formula (II) are respectively (S, R). 
Ry Ba pri čemu je stereoizomerna konfiguracija ugljenik-1 i ugljenik-3 respektivno (S, R) ili (5,5), i pri čemu Rž je cikloheksil i R*' je OR
A process for producing a pharmaceutical composition as claimed in any one of Claims 1-15 which comprises providing a solid form of a therapeutically effective amount of octreotide and a solid form comprising a medium chain fatty acid salt, and suspending the solid forms in a hydrophobic medium, to produce a suspension containing in solid form the octreotide and the medium chain fatty acid salt, thereby producing the pharmaceutical composition, wherein the pharmaceutical composition contains 10% or more by weight of medium chain fatty acid salt. 
Postupak za proizvodnju farmaceutskog pripravka kao što je navedeno u bilo kojem od patentnih zahtjeva 1-15 naznačen time da sadrži osiguravanje krutog oblika terapeutski učinkovite količine oktreotida i kruti oblik koji sadrži sol masne kiseline srednjeg lanca, te suspendiranje krutih oblika u hidrofobnom mediju, da se dobije suspenzija koja sadrži oktreotid u krutom obliku i sol masne kiseline srednjeg lanca, čime se proizvodi farmaceutski pripravak, pri čemu farmaceutski pripravak sadrži 10 masenih % ili više soli masne kiseline srednjeg lanca.
A method for delivery of messenger RNA (mRNA) for in vivo production of a secreted polypeptide, comprising administering, to a human, a composition comprising an mRNA that encodes the secreted polypeptide wherein the mRNA is encapsulated within a lipid nanoparticle, wherein the administering of the composition results in expression of the secreted polypeptide encoded by the mRNA that is detectable in serum at least 72 hours after administration, and wherein the lipid nanoparticle comprises one or more PEG-modified lipids. 
Sastav koji sadrži (a) najmanje jednu molekulu mRNA čiji najmanje jedan dio kodira funkcionalni izlučeni polipeptid; i (b) liposomalni nosač za prijenos koji sadrži lipidnu nanočesticu koja sadrži jedan ili više kationskih lipida, jedan ili više nekationskih lipida i jedan ili više lipida modificiranih s PEG, za upotrebu u postupku liječenja subjekta s oštećenjem ili nedostatkom u navedenom izlučenom polipeptidu, pri čemu je mRNA kapsulirana u nosač za prijenos i pri čemu se sastav primjenjuje isporukom u pluća putem nebulizacije.